Hims & Hers Health (HIMS) Fires Up Revenue Growth as Subscribers Climb; Guidance Tweaked for 2026

Ticker: HIMS • EPS not disclosed in this release; earnings surprise and EPS consensus figures are not provided here. revenue forecast remains focused on full-year revenue guidance for 2026.

A quarter of momentum with a cautious dashboard

Hims & Hers Health, Inc. released its third-quarter numbers for 2026, signaling a convincing acceleration in top-line growth driven by a growing customer base and a resumption of international expansion. The company reported approximately $890 million in revenue for the quarter, marking a 49% year-over-year increase. Subscribers rose to about 2.8 million, up roughly 13% from a year earlier. These lines reflect not just more customers, but a platform that is increasingly able to monetize a larger cohort over time.

Key metrics at a glance

Revenue: ≈ $890 million in Q3 2026, up 49% YoY.
Subscribers: Nearly 2.8 million, up ~13% YoY.
Geographic mix: Domestic revenue up 21% YoY; international revenue up more than 300% YoY, underscoring a rapid scale in non-core markets.
Guidance: Full-year 2026 revenue forecast narrowed to $3.13 billion to $3.15 billion; Adjusted EBITDA guidance narrowed to $257 million to $277 million.

Guidance and what it implies

The company tightened its revenue forecast for the full year 2026 while dialing the Adjusted EBITDA range down slightly. In the CFO’s words, the plan includes deliberate marketing pacing in support of platform expansions slated for the fourth quarter and into 2027. That suggests management is balancing near-term growth ambition with a desire to preserve balance-sheet strength and durable cash flow generation.

In practical terms, the Q3 print reinforces the thesis that Hims & Hers is not just chasing subscribers, but sculpting a platform where the customer relationship becomes increasingly stickier and monetizable. The international surge—more than triple-digit growth—hints at a multi-year expansion thesis, albeit with revenue quality and profitability considerations that will matter to investors watching the revenue forecast trajectory into 2027.

Executive color and optics

“In healthcare, whoever owns the customer relationship wins,” affirmed CEO Andrew Dudum, framing a long-run strategic bet on a platform that combines treatment options, care teams, and an AI-native underpinning to support consumer decisions across categories and markets.

CFO Yemi Okupe added that the company benefited from growth momentum while deliberately pacing marketing to align with planned platform expansions. The stance implies that profitability could hinge on how efficiently the new markets scale and how well the marketing mix converts adoption into sustainable revenue streams.

What this could portend for HIMS and peers

The quarterly cadence shows a company that is growing faster than its mature peers yet remains mindful of the path to adjusted profitability. The robust international growth signals an opportunity for Hims & Hers to diversify away from domestic volatility and currency headwinds, though execution risk in new geographies—regulatory, competitive, and logistical—will bear watching.

For the sector, the results underscore the viability of a vertically integrated health-and-wellness platform model that leans on a subscription-like approach and scalable marketing. Peers focusing on direct-to-consumer health services could benefit from consumer education and broader product suites, provided they translate subscriber gains into meaningful EBITDA improvements. The absence of a disclosed GAAP or EPS metric in this release makes the story more about revenue quality and lifetime value rather than a snapshot of quarterly earnings per share. Still, the market will keep an eye on the EPS consensus landscape as peers report; for HIMS, the delta between revenue growth and profitability remains the substantive question.

Bottom line and takeaways

Revenue trajectory remains strong, with a 49% YoY quarterly uplift and an ambitious 2026 revenue forecast.
Subscriber base continues to expand, reinforcing the platform’s scale and cross-sell potential.
International growth is a standout, potentially a multi-year driver if expansion costs moderate and localization efforts pay off.
Profitability remains a focal point; guidance for Adjusted EBITDA provides a compass for investors watching margin progression alongside growth.

Sector peers: what to watch next

As digital-health ecosystems mature, the pressure is on translating user growth into durable cash flow. If HIMS can sustain international momentum while maintaining unit economics, the model could widen the competitive moat around platform-based health services. Sector peers may try to emulate the combination of broad product expansion, care-team orchestration, and AI-assisted experience—but they’ll need disciplined spending and a clear path to EBITDA expansion to avoid the creeping risk of high marketing burn without equivalent monetization.